Background: Caffeine citrate is the treatment of choice for apnea of prematurity (AOP). Regulatory agencies have requested real-world data on drug utilization and safety, a postauthorization safety study, of a pharmaceutical-grade caffeine citrate, Peyona®, to confirm its benefit for preterm infants. Objectives: To investigate the clinical use, outcomes, and safety profile of this pharmaceutical-grade caffeine citrate in the routine treatment of preterm infants with a gestational age (GA) <37 weeks. Methods: We conducted a multicenter, noninterventional, prospective study in five European countries. Patients eligible for study enrollment were <37-week GA neonates who received treatment with the pharmaceutical-grade caffeine citrate and whose parents had given informed consent. Results: A total of 506 preterm infants were enrolled from 21 institutions. The pharmaceutical-grade caffeine citrate doses were administered intravenously, orally, or via both routes. The main indication of use was AOP treatment (58%) followed by AOP prophylaxis (37%). Median treatment duration was 21 days. The primary cause of study termination was AOP resolution (n = 407; 80%). Hundred and six patients (21%) required supplemental oxygen on day 28; 48 patients (9.5%) had bronchopulmonary dysplasia at 36 weeks' postmenstrual age. Twenty-three adverse drug reactions were observed in 21 neonates (4.2%); the most frequent was tachycardia (2.3%) and only one (seizures) was considered serious. Thirty-one patients (8.1%) had hepatic or renal functional impairment; the side effects were manageable, and these patients also benefitted from treatment. Conclusions: The use of this caffeine citrate is safe for the management of AOP in a real-world setting.

Keywords:
Preterm infants, Caffeine citrate, Apnea
1.
Schoen K, Yu T, Stockmann C, Spigarelli MG, Sherwin CM: Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity. Paediatr Drugs 2014;16:169-177.
2.
Finer NN, Higgins R, Kattwinkel J, Martin RJ: Summary proceedings from the apnea-of-prematurity group. Pediatrics 2006;117:S47-S51.
3.
Vatlach S, Arand J, Engel C, Poets CF: Safety profile comparison between extemporaneous and a licensed preparation of caffeine citrate in preterm infants with apnea of prematurity. Neonatology 2014;105:108-111.
4.
Henderson-Smart DJ, Steer PA: Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev 2010;1:CD000273.
5.
Henderson-Smart DJ, Davis PG: Prophylactic methylxanthines for extubation in preterm infants. Cochrane Database Syst Rev 2003;1:CD000139.
6.
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al: Caffeine therapy for apnea of prematurity. N Engl J Med 2006;354:2112-2121.
7.
Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al: Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med 2007;357:1893-1902.
8.
Schmidt B, Anderson PJ, Doyle LW, Dewey D, Grunau RE, Asztalos EV, et al; Caffeine for Apnea of Prematurity (CAP) Trial Investigators: Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity. JAMA 2012;307:275-282.
9.
Dukhovny D, Lorch SA, Schmidt B, Doyle LW, Kok JH, Roberts RS, et al; Caffeine for Apnea of Prematurity Trial Group: Economic evaluation of caffeine for apnea of prematurity. Pediatrics 2011;127:e146-e155.
10.
Morley CJ, Davis PG, Doyle LW, Brion LP, Hascoet JM, Carlin JB, et al: Nasal CPAP or intubation at birth for very preterm infants. N Engl J Med 2008;358:700-708.
11.
Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al: Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005;116:1353-1360.
12.
Skouroliakou M, Bacopoulou F, Markantonis SL: Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. J Paediatr Child Health 2009;45:587-592.
13.
Steer P, Flenady V, Shearman A, Charles B, Gray PH, Henderson-Smart D, et al: High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal 2004;89:F499-F503.
14.
Ulanovsky I, Haleluya NS, Blazer S, Weissman A: The effects of caffeine on heart rate variability in newborns with apnea of prematurity. J Perinatol 2014;34:620-623.
15.
Francart SJ, Allen MK, Stegall-Zanation J: Apnea of prematurity: caffeine dose optimization. J Pediatr Pharmacol Ther 2013;18:45-52.
16.
Beath SV: Hepatic function and physiology in the newborn. Semin Neonatol 2003;8:337-346.
17.
Guignard JP: Renal function in the newborn infant. Pediatr Clin North Am 1982;29:777-790.
18.
Ligi I, Boubred F, Grandvuillemin I, Simeoni U: The neonatal kidney: implications for drug metabolism and elimination. Curr Drug Metab 2013;14:174-177.
19.
Bueva A, Guignard JP: Renal function in preterm neonates. Pediatr Res 1994;36:572-577.
20.
Vanpee M, Blennow M, Linne T, Herin P, Aperia A: Renal function in very low birth weight infants: normal maturity reached during early childhood. J Pediatr 1992;121:784-788.
21.
Fischer HS, Bührer C: Avoiding endotracheal ventilation to prevent bronchopulmonary dysplasia: a meta-analysis. Pediatrics 2013;132:e1351-e1360.
22.
Schmölzer GM, Kumar M, Pichler G, Aziz K, O'Reilly M, Cheung P: Non-invasive versus invasive respiratory support in preterm infants at birth: systematic review and meta-analysis. BMJ 2013;347:f5980.
23.
Walsh MC, Morris BH, Wrage LA, Vohr BR, Poole WK, Tyson JE, et al: Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005;146:798-804.
24.
Patel RM, Leong T, Carlton DP, Vyas-Read S: Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol 2013;33:134-140.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.